Logo do repositório
 
Publicação

Impact of high‐risk human papilloma virus genotyping in cervical disease in the Northern region of Portugal: real‐world data from regional cervical cancer screening program

2023Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorRosário, Andreia
dc.contributor.authorSousa, Ana Saraiva
dc.contributor.authorMarinho-Dias, Joana
dc.contributor.authorMedeiros, Rui
dc.contributor.authorLobo, Cláudia
dc.contributor.authorLeça, Luís
dc.contributor.authorCoimbra, Nuno
dc.contributor.authorTavares, Fernando
dc.contributor.authorBaldaque, Inês
dc.contributor.authorMartins, Maria Gabriela
dc.contributor.authorMonteiro, Paula
dc.contributor.authorHenrique, Rui
dc.date.accessioned2023-01-06T15:38:43Z
dc.date.available2023-01-06T15:38:43Z
dc.date.issued2023
dc.description.abstractCervical cancer prevention is based on primary prevention with vaccines againstHuman Papillomavirus (HPV) and secondary prevention by screening with High‐Risk‐HPV (Hr‐HPV) detection. Since 2017, cervical cancer screening in women aged25−60 years has been performed in Portugal using Hr‐HPV detection, followed bycytology in Hr‐HPV‐positive cases. Herein we report the prevalence of Hr‐HPVgenotypes and cytological abnormalities among 462 401 women (mean age:43.73 ± 10.79; median age: 45; range: 24−66 years) that participated in the RegionalCervical Cancer Screening Program of the Northern Region of Portugal, performedbetween August 2016 and December 2021. Overall, we describe a prevalence rateof 12.50% for Hr‐HPV varying from 20.76% at age 25% to 8.32% at age 64. The fivemost common Hr‐HPV genotypes identified were HPV‐68 (16.09%), HPV‐31(15.30%), HPV‐51 (12.96%), HPV‐16 (11.06%), and HPV‐39 (11.01%). Theprevalence of Hr‐HPV included in the nonavalent vaccine (HPV‐9valent) was55.00% ranging from 47.78% to 59.18% across different age groups.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRosário, Andreia; Saraiva Sousa, Ana; Marinho-Dias, Joana; Medeiros, R; Lobo, Cláudia; Leça, Luís; Coimbra, Nuno; Tavares, Fernando; Baldaque, Inês; Martins, Maria Gabriela; Monteiro, Paula; Henrique, Rui (2023). Impact of high‐risk human papilloma virus genotyping in cervical disease in the Northern region of Portugal: real‐world data from regional cervical cancer screening program. Journal of Medical Virology. ISSN 1096-9071. 95:1, p. 1-11pt_PT
dc.identifier.doi10.1002/jmv.28414
dc.identifier.issn1096-9071
dc.identifier.urihttp://hdl.handle.net/10198/26394
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWILEYpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectHuman papillomaviruspt_PT
dc.subjectCervical cancerpt_PT
dc.subjectGenotypingpt_PT
dc.subjectPrevalencept_PT
dc.subjectScreeningpt_PT
dc.subjectVaccinept_PT
dc.titleImpact of high‐risk human papilloma virus genotyping in cervical disease in the Northern region of Portugal: real‐world data from regional cervical cancer screening programpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceUnited Statespt_PT
oaire.citation.endPage11pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleJournal of Medical Virologypt_PT
person.familyNameSousa
person.givenNameAna Saraiva
person.identifier.ciencia-idAB17-B086-334A
person.identifier.orcid0000-0002-3128-3328
person.identifier.scopus-author-id57194322385
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication7251c1ca-3d6d-476a-af85-d18c956f909f
relation.isAuthorOfPublication.latestForDiscovery7251c1ca-3d6d-476a-af85-d18c956f909f

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Impact of high‐risk Human Papillomaviru.pdf
Tamanho:
2.71 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.75 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESSa - Artigos em Revistas Indexados à WoS/Scopus